Based on the information available, there is no definitive answer regarding the long-term safety of lurbinectedin when used with chemotherapy. Lurbinectedin is a novel anticancer drug that has shown promising results in treating small cell lung cancer and other solid tumors [1]. However, the drug's long-term safety profile has not been extensively studied, and there is limited information available on its use for extended periods.

Clinical trials, such as the one conducted by PharmaMar, have focused on the drug's efficacy and short-term safety [2]. While the trials may provide some insight into potential long-term effects, they are not designed to evaluate the safety of lurbinectedin over an extended period.

It is important to note that, like all medications, lurbinectedin may have side effects, some of which may be severe or persistent. Common side effects include neutropenia, anemia, thrombocytopenia, fatigue, nausea, and increased liver enzymes [3]. The long-term implications of these side effects are not well understood.

In summary, based on the available information, there is no definitive answer regarding the long-term safety of lurbinectedin when used with chemotherapy. Patients and healthcare providers should carefully weigh the potential benefits and risks of this treatment, considering the limited information on long-term safety. Consulting with an experienced oncologist and monitoring the patient's response to the therapy is crucial for ensuring safe and effective cancer treatment.

Sources:

1. DrugPatentWatch.com. Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>
2. PharmaMar. A Phase II, open-label, multicenter study to evaluate the efficacy and safety of lurbinectedin in patients with small cell lung cancer (SCLC) progressing after first-line chemotherapy. ClinicalTrials.gov. <https://clinicaltrials.gov/ct2/show/NCT02454972>
3. FDA. Lurbinectedin. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214437s000lbl.pdf>